Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

Inclusion Criteria

• •Age ≥ 18 years old and \<75 years old
• •Woman on childbearing age should be on effective contraception during the duration of the study and up to 6 months after treatment; a mechanical contraception (use of condom) will be strongly recommended
• •Male (effective contraception must be used during duration of the study and up to 3 months after treatment)
• •Patient with a first infection with Mycobacterium tuberculosis of pulmonary localization suspected by the presence of a clinical pulmonary symptomatology, a chest X-ray or an abnormal chest computed tomography, and the positive microscopic examination of a sputum (AFB +, presence of AFB) with confirmation of tuberculosis by a genotypic test demonstrating no resistance to rifampicin, without clinical signs of extra-thoracic involvement
• •State medical assistance application being processed ( If patient does not benefit from social security),
• •Signature of informed consent
• •Neoplastic pathology during treatment with chemo and / or radiotherapy;
• •Decompensated cirrhosis;
• •Pregnancy, desire to become pregnant, breast-feeding (for women of childbearing potential, contraception should be used for the duration of the study and up to 6 months after treatment, mechanical contraception will be strongly recommended and up to 3 months after treatment);
• •Protected adults (under guardianship, curatorship) and under safeguard of justice
• •Significant laboratory abnormalities (hemoglobin \<9g / dl, polynuclear neutrophils \<500 / mm3, platelets \<50,000 / mm3, creatinine clearance \<30ml / min, ASAT or ALAT\> 3N, and total bilirubin\> 3N)
• •Hyperuricaemia
• •Porphyria
• •Optic neuritis or peripheral neuropathy
• •BMI≤ 16 kg/m2
• •Participation in other interventional research
• •Current treatment with one or more medications contraindicated in combination with linezolid: Linezolid should not be used in patients treated with monoamine oxidase A or B inhibitors (for example: phenelzine, isocarboxacid, selegiline, moclobemide) or who received one of these products in the previous two weeks
• •Current treatment with one or more medications contraindicated in combination with quadritherapy:
• •Combination with bictegravir, cobicistat, daclatasvir, dasabuvir, delamanid, grazoprevir/elbasvir, protease inhibitors boosted by ritonavir, isavuconazole, ledipasvir, lurasidone, midostaurin, ombitasvir/paritaprevir, praziquantel, rilpivirine, sofosbuvir, velpatasvir, voriconazole, voxilaprevir
• •Gastrointestinal topicals, antacids and adsorbents and salts and aluminum hydroxides